- Competition closes: 01 December 2021, 11am
- Applicants notified: 24 January 2022
- Project start date & duration: 01 April 2022; between 3 and 24 months
This competition combines the feasibility and primer strands of the Biomedical Catalyst to explore and evaluate the commercial potential of an innovative scientific idea, or to carry out a technical evaluation through to proof of concept in a model system. Projects must focus developing a product or process that is an innovative solution to a defined health or care challenge. Your project can focus on:
- disease prevention and proactive management of health and chronic conditions
- earlier and better detection and diagnosis of disease, leading to better patient outcomes
- tailored treatments that either change the underlying disease or offer potential cures
Your project can:
- review research evidence and identify possible applications
- assess business opportunities
- assess or protect intellectual property
- validate initial concepts and existing pre-clinical work through experimental studies
- initially demonstrate using in-vitro and in-vivo models, but not human clinical trials
- develop early-stage prototyping
- acquire preliminary regulatory advice
Feasibility Award: Designed for projects that have developed an innovative concept or carried out experimental proof of concept but have not validated the technology. The aim of the feasibility award is to explore and evaluate the commercial potential of innovative ideas.
Primer Award: For conducting a technical evaluation of an idea through to proof of concept in a model system.
Projects can focus on any health and care sector or discipline. Applications that support innovations in the following areas are welcomed:
- child health technologies;
- innovations that support clinical trials in the UK;
- biomedical innovations that combat the threat of antimicrobial resistance.
Projects can align with one of these innovation areas (non-exhaustive list):
- medical technologies and devices;
- stratified healthcare;
- advanced therapies (gene and cell therapies);
- digital health;
- drug discovery;
Projects that will not be funded
- not related to human life sciences
- already on the market
- laboratory accreditation
- distribution or marketing activity, post-marketing studies and post-marketing surveillance
- dependent on export performance – for example giving a subsidy to a baker on the condition that they export a certain quantity of bread to another country.
- dependent on domestic inputs usage- for example if they insisted that a baker use 50% UK flour in their product
We will not support innovation projects conducted to anything less than the highest standards of animal welfare.
- Subsidy Control and EC State Aid funding rules apply
- Project must be led by a UK business of any size and collaborators must be UK based organisations
- R&D work must be carried out in the UK and project results exploited from UK.
- Subcontractors can be from UK/overseas, with costs justified and appropriate to the total eligible project costs.
- Total eligible project costs between £50,000 and £1M (£12M pot).
- For feasibility studies and industrial research projects, you could get funding for your eligible project costs of:
- Micro/small business <70%
- Medium sized business <60%
- Research organisations in your consortium can share up to 50% of the total eligible project costs.